Skip to content
OpenCapital
Get started

Artiva Biotherapeutics, Inc. ARTV Stock Shares Authorized Temporary And Permanent Shares

Other financials

Income statement

See full
Revenue-—
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%—
Net margin-79.3%—

Returns & leverage

See full
Return on equity-67.9%—
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept artv:StockSharesAuthorizedTemporaryAndPermanentShares.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s stock shares authorized temporary and permanent shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s stock shares authorized temporary and permanent shares?
Artiva Biotherapeutics, Inc. (ARTV) reported stock shares authorized temporary and permanent shares of 710M in Q3 2024.